The term “thyroid tsab” generally refers to TSAb, or thyroid-stimulating antibodies, which, in contrast to thyroid-stimulating hormone-binding inhibitory immunoglobulins, reflect the fact that these antibodies not only bind to the thyroid-stimulating hormone receptor but also exert a stimulatory function on thyroid cells. Clinical studies have found that 85% to 100% of newly diagnosed patients with Graves’ disease are positive for thyroid-stimulating antibodies. tSAb activity averages 200% to 300%. When the test found that the thyroid stimulating antibodies are positive, the cause of the disease should be clarified under the guidance of a professional endocrinologist, and active treatment should be carried out to avoid delays in the diagnosis and treatment of the disease.